39 related articles for article (PubMed ID: 34678571)
1. Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers.
Chen HL; Huang FB; Chen Q; Deng YC
BMC Cancer; 2023 Sep; 23(1):841. PubMed ID: 37684569
[TBL] [Abstract][Full Text] [Related]
2. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
Yoder R; Kimler BF; Staley JM; Schwensen K; Wang YY; Finke K; O'Dea A; Nye L; Elia M; Crane G; McKittrick R; Pluenneke R; Madhusudhana S; Beck L; Shrestha A; Corum L; Marsico M; Stecklein SR; Godwin AK; Khan QJ; Sharma P
NPJ Breast Cancer; 2022 Jul; 8(1):80. PubMed ID: 35817765
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer.
Luo C; Zhong X; Fan Y; Wu Y; Zheng H; Luo T
Breast; 2022 Jun; 63():24-28. PubMed ID: 35279509
[TBL] [Abstract][Full Text] [Related]
4. Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade.
Bae SJ; Kim JH; Lee MJ; Baek SH; Kook Y; Ahn SG; Cha YJ; Jeong J
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398233
[TBL] [Abstract][Full Text] [Related]
5. The Clinical and Pathological Characteristics That Differentiate Cases With "Low Estrogen Receptor Expression" From Triple-Negative Breast Cancer.
Karaali C; Emiroğlu M; Değirmenci M; Keser M; Salimoğlu S; Kelten Talu C
Eur J Breast Health; 2024 Jan; 20(1):19-24. PubMed ID: 38187108
[TBL] [Abstract][Full Text] [Related]
6. Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Higgins T; Kantor O; Harrison B; Giordano J; McGrath M; Burstein HJ; Schnitt SJ; Rahman T; Vora H; Garrido-Castro A; Tolaney SM; Meric-Bernstam F; King TA; Mittendorf EA
Ann Surg Oncol; 2024 Apr; 31(4):2244-2252. PubMed ID: 38161200
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives.
Malainou CP; Stachika N; Damianou AK; Anastopoulos A; Ploumaki I; Triantafyllou E; Drougkas K; Gomatou G; Kotteas E
Curr Oncol; 2023 Nov; 30(11):9734-9745. PubMed ID: 37999126
[TBL] [Abstract][Full Text] [Related]
8. Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer.
Murto MO; Simolin N; Arponen O; Siltari A; Artama M; Visvanathan K; Jukkola A; Murtola TJ
JAMA Netw Open; 2023 Nov; 6(11):e2343861. PubMed ID: 37976058
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer.
Shikata S; Murata T; Yoshida M; Hashiguchi H; Yoshii Y; Ogawa A; Watase C; Shiino S; Sugino H; Jimbo K; Maeshima A; Iwamoto E; Takayama S; Suto A
Sci Rep; 2023 Nov; 13(1):19669. PubMed ID: 37952045
[TBL] [Abstract][Full Text] [Related]
10. Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL.
Zhang X; Zhao P; Ma M; Wu H; Liu R; Liu Z; Cai Z; Liu M; Xie F; Ma X
Front Med (Lausanne); 2023; 10():1168977. PubMed ID: 37457559
[TBL] [Abstract][Full Text] [Related]
11. Immune landscape of breast tumors with low and intermediate estrogen receptor expression.
Voorwerk L; Sanders J; Keusters MS; Balduzzi S; Cornelissen S; Duijst M; Lips EH; Sonke GS; Linn SC; Horlings HM; Kok M
NPJ Breast Cancer; 2023 May; 9(1):39. PubMed ID: 37179445
[TBL] [Abstract][Full Text] [Related]
12. Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.
Reinert T; Cascelli F; de Resende CAA; Gonçalves AC; Godo VSP; Barrios CH
Front Endocrinol (Lausanne); 2022; 13():1015388. PubMed ID: 36506043
[TBL] [Abstract][Full Text] [Related]
13. Emerging Targeted Therapies for Early Breast Cancer.
Schlam I; Tarantino P; Morganti S; Lynce F; Trapani D; Mayer EL; Garrido-Castro AC; Waks A; Tolaney SM
Drugs; 2022 Sep; 82(14):1437-1451. PubMed ID: 36207645
[TBL] [Abstract][Full Text] [Related]
14. Role of Estrogen Receptor-Positive/Negative Ratios in Regulating Breast Cancer.
Li Y; Zhang H; Jiang T; Li P
Evid Based Complement Alternat Med; 2022; 2022():7833389. PubMed ID: 36118080
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by
Sandoval RL; Polidorio N; Leite ACR; Cartaxo M; Pisani JP; Quirino CV; Cezana L; Pereira NG; Pereira AAL; Rossi BM; Achatz MI
Front Oncol; 2022; 12():836937. PubMed ID: 35371985
[TBL] [Abstract][Full Text] [Related]
16. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.
Dinh P; Graham JD; Elder EN; Kabir M; Doan TB; French J; Meybodi F; Hui R; Wilcken NR; Harnett PR; Hsu J; Stuart KE; Wang T; Ahern V; Brennan M; Fox SB; Dear RF; Lim E; White M; Mann GB; Pathmanathan N
Breast Cancer Res Treat; 2022 Feb; 191(3):501-511. PubMed ID: 34853987
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis.
Paakkola NM; Karakatsanis A; Mauri D; Foukakis T; Valachis A
ESMO Open; 2021 Dec; 6(6):100289. PubMed ID: 34678571
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
